| Development code number |
Class or application |
Developmental stage |
| CS-747 (prasugrel) |
Oral antiplatelet agent |
NDA submitted |
| CS-011 (rivoglitazone) |
Diabetes (PPAR) |
Phase III |
| CS-8635 |
Cardiovascular disease |
Phase III |
| DU-176b |
Anticoagulant.(Factor Xa Inhibitor) |
Phase II |
| CS-1008 |
Oncology (DR5) |
Phase II |
| SUN-11031 |
Human grehlin/cachexia |
Phase II |
| CS-8958 |
Anti-influenza |
Phase II |
| CS-7017 |
Oncology (PPAR gamma) |
Phase I |
| CS-0777 |
Immunosuppressive |
Phase I |
| DB-772d |
Oral Factor Xa inhibitor |
Phase I |
| CS-8080 |
Anti-arteriosclerosis |
Phase I |
| SUN-13834 |
Chymase inhibitor |
Phase I |
|
|
